What is EPIRUS Biopharmaceuticals, Inc. (EPRSQ)?

EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of EPRSQ?

The current price of EPRSQ is $0.00. Prices are updated in real time on Stocks360.

What is EPRSQ's market capitalization?

EPRSQ's market capitalization is $1,571.00, placing it in the small-cap tier.

EPIRUS Biopharmaceuticals, Inc. (EPRSQ)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$1.57K

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

-14.11

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

150.00

EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $1.57K. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 10, 2016

EPS $-0.66 vs est. $-0.54

Missed by $0.12

Proprietary Signals

Signal snapshot temporarily unavailable.

About EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions. The company's developmental portfolio also encompassed several other biosimilar candidates: BOW050, a biosimilar version of Humira (adalimumab), targeting inflammatory diseases such as rheumatoid arthritis, various adult and pediatric forms of arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis. BOW070, mimicking Actemra (tocilizumab), aimed at rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. BOW080, a biosimilar to Soliris, designed to address ultra-rare blood disorders like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. BOW100, a biosimilar of SIMPONI, for inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. EPIRUS had established strategic alliances, including a licensing arrangeme…